Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20085646 | 0.94 | ALK (1.00) | ALKINSR | |
| SCHEMBL18159098 | 0.90 | ALK (1.00) | ALKINSR | |
| SCHEMBL20087316 | 0.87 | ALK (1.00) | ALKINSR | |
| SCHEMBL20085663 | 0.86 | ALK (0.84) | ALKINSR | |
| SCHEMBL20085664 | 0.86 | ALK (0.84) | ALKINSR | |
| SCHEMBL20085726 | 0.85 | ALK (1.00) | ALKINSR | |
| SCHEMBL18159160 | 0.85 | ALK (0.85) | ALKINSR | |
| SCHEMBL18159082 | 0.84 | ALK (0.82) | ALKINSR | |
| SCHEMBL20085690 | 0.84 | ALK (0.79) | ALKINSR | |
| SCHEMBL18159220 | 0.83 | ALK (1.00) | ALKINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180111905-A1 | N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-04-26 | — | — | US | disclosed |
| WO-2016167511-A2 | N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111905-A1 | N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT | ALK, NPM1, EML4 | ALK 1/4885INSR 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.